환인제약

016580KOSPI

58.5 / 100

Reference Date: 2026-10-23

Financial Score25.0 / 40

News Sentiment12.5 / 25

Momentum11.0 / 20

Disclosure10.0 / 15

AI Analysis: the debt ratio is very low with excellent financial health but Operating Profit is on a declining trend. Slightly up 1.4% over the past month, with no recent news.

Company InformationBased on 2025 Annual Report

Business Overview

Hwanin Pharmaceutical primarily engages in the manufacturing and sales of pharmaceuticals, with psychiatric and neurological drugs accounting for over 80% of total revenue. According to the 2024 IMS DATA, the company holds the top position in the domestic psychotropic drug market. Its affiliated subsidiaries, Ambrobi&F and Asyu, focus on pharmaceutical R&D and comprehensive distribution, respectively.

Number of Employees

671people

Average Salary

75.3M KRW

Score Calculation Basis

Detailed Financial Score

PER

11.87Industry Average 15.005.0Point

In line with industry avg

PBR

0.45Industry Average 1.207.0Point

Half of industry avg (excellent)

ROE

3.41Industry Average 8.001.0Point

Well below industry avg

Debt Ratio

0.33Industry Average 100.008.0Point

Half of industry avg (excellent)

Trend 2023~20254.0 / 10 points

Revenue Growth Rate

2.0 / 3

Avg ▲5.5% (2-year basis)

Operating Profit Growth Rate

0.0 / 3

Avg ▼34.1% (2-year basis)

ROE Trend

2.0 / 4

Avg ROE 6.1% (declining, 3yr)

Detailed News Sentiment

0 totalPositive 0Neutral 0Negative 0

Detailed Momentum

52-week position3.0Point

52w lower range (34%)

Current 10,170Won52-week high 11,93052-week low 9,230

1-month return3.0Point

1m 1.4% (flat)

Volume trend5.0Point

Volume increasing

Detailed Disclosure

0 totalPositive 0Neutral 0Negative 0